Key Takeaways
- Own-label pivot resets U.S. growth: Caplin Steriles revenue was flat YoY as the company deliberately stopped exclusive B2B deals to launch its own U.S. label, a conscious trade-off that sacrifices near-term growth for mid-term margin capture.
- Gross margins hold above 60%: Gross margin came in at 60.4%, the second-highest ever, while COGS has been structurally reduced from 48% to 40% of revenue since FY20.
- Oncology turns profitable in year one: The oncology business delivered INR 34 crores in its first full year of operations, validating the diversification thesis.
- Employee costs surge on structural expansion: Employee expenses rose over 25% YoY for the second straight quarter, driven by new U.S. and Caplin One subsidiaries, ESOP charges, LatAm hires, and advance hiring for upcoming commercial production.
- What to watch next quarter: The pace of own-label launches (targeting ~20 by March-end vs 11 now), whether the 13 ANDAs under FDA review begin converting to approvals, and the trajectory of Caplin Steriles revenue as the B2B-to-own-label mix shifts.
The Own-Label Pivot: Caplin Steriles Strategy Shift
- The trade-off: Caplin Steriles took a conscious decision 8-9 months ago to stop doing exclusive B2B deals with large upfront milestone payments, pivoting instead to launching its own label in the U.S. This caused revenue to moderate to a largely flat INR 87.8 crores this quarter.
- The payoff: Previously, the company did transfer pricing with a 50% profit share to front-end partners. By launching its own label, that 50% now accrues directly back to Caplin Steriles over the mid-to-long term.
- Launch momentum: 11 products have already been launched under the Caplin Steriles own label; before the end of FY25 this will jump to approximately 20, and before the end of next year, approximately 50.
- B2B will not disappear: The company will always do some B2B and CMO business to keep capacities fully used, especially as Phase III expansion adds five more lines, but own-label takes precedence going forward.
- Transition is open-ended: Management declined to put a timeline on when the transition will be completed, saying it "probably will not be entirely completed at all," though over the next 3-5 years own-label will certainly be larger than B2B.
- Cash flow self-sufficiency: Despite heavier opex spend, larger ANDA spend, and crossing 20 ANDAs, Caplin Steriles has lived within its means and not gone back to the parent for working capital, owing only the capex loan.
Vivek Partheeban: "We should remember that we took a conscious call as a company that we are going to be launching a label of our own in the U.S., right? So when that be the case, at least almost around eight to nine months ago, we stopped doing these exclusive deals where we take on a large milestone payment upfront."
U.S. Business: Approvals, Targets & Pipeline
- Approved products going live: All 28 approved products are to be launched within the coming few weeks; the company is geared up for the same.
- ANDAs under review: 13 products are under review with the FDA, a mix of injectable suspensions, injectable emulsions, ready-to-use bags and ophthalmic products; management hopes to receive all approvals within the coming 12 months.
- Recent approvals signal complexity: Two ready-to-use bag products and five or six ophthalmic products were recently approved, including one ophthalmic emulsion that is highly complex and received a first-cycle approval.
- Revenue target maintained: Management reiterated confidence in the overall U.S. target of hitting $100 million by FY27-FY28, though it declined to provide specific guidance for next year or break down the growth rate required to get there.
- Own-label traction: The U.S. own label launched in November and generated a little over $0.5 million in revenue within the first couple of months.
- Direct sales ambition: The long-term objective is to go as direct as possible targeting large markets, a mid-to-long-term target.
- ANDAs acquisition discussions: The company is in active discussions with other players to acquire ANDAs in the injectable and ophthalmic space, using cash reserves for targets not in its internal pipeline or products it cannot manufacture, such as antibiotics.
Latin America: The Next Growth Frontier
- Mexico registrations secured: The company received 10 registrations from Mexico and has filed 28 products; real growth is expected to start maybe one year from now.
- Chile entry imminent: A person has been appointed with exposure in the Chilean market, who will also cover Brazil, Uruguay and Paraguay for registrations; Chilean business will start consistently from July.
- Contract manufacturing in Mexico: Two factories have been identified for oral solid, ointments and suppositories contract manufacturing in Mexico, with 10 products identified and dossiers for 40-45 products getting ready.
- Mexico strategy differentiated: Unlike Central America where the company replaced importers, in Mexico it will replace wholesalers and create a niche there.
- LatAm doubling ambition: Management is confident of at least doubling the entire Latin American business in the next five years.
- Conventional LatAm growth: The parent company's conventional LatAm business grew 14% this quarter.
- Colombia and Brazil are mid-to-long-term targets in the region.
C.C. Paarthipan: "See, until now, we have been competing with companies of our size. Now we are in the big boys playground. We need to position ourselves in a unique place that alone can take us actually to the next orbit."
Margins & Cost Structure
- Gross margin near peak: Gross margin at 60.4% is the second-highest ever, surpassing the committed 55% by over 500 bps, driven by COGS reduction from 48% in FY20 to 40% now.
- Opex discipline holds: Despite employee strength almost doubling and more factories coming up, operating expenses remain around 25%-26% of revenue.
- Employee cost surge unpacked: The steep YoY increase is driven by new U.S. subsidiary employee costs (INR 5.36 cr), Caplin One entity (INR 3.23 cr), ESOP expenses (INR 5.3 cr over last year), LatAm subsidiaries (INR 3.69 cr), and CPL parent entity (INR 4.96 cr), plus advance hiring for upcoming commercial production and software development.
- Currency tailwind modest: Out of the INR 195 crores revenue increase, only INR 18 crores (10%) came from USD appreciation.
- Margin sustainability: Management is confident margins will not become marginal and expects to do better than before after 3-3.5 years, though it did not directly answer whether current margins represent a peak or whether they can revert to the 28%-32% EBITDA range.
- Tax rate normalization: The company previously had incurring losses; now those entities have turned profitable and management says it will be "more than happy to pay taxes."
Pipeline: Complex Products & New Capabilities
- Four high-tech products in development: These have an outer-limit commercialization timeline of 24 to 30 months, though management called revenue projections premature given dynamic markets and unknown competition.
- Semaglutide tablets: Patent expiring in many countries by 2026; two groups of private R&D are engaged on this alongside MC-1 (a new chemical entity), specialty products, and biosimilars.
- Insulin sourcing begun: The company has already started outsourcing insulin from China for the LATAM market and will look at the possibility of manufacturing insulin at a later date.
- Biosimilars: The company is talking to a couple of companies for API sourcing and will do formulation in its own factory for ROW markets.
- API captive consumption: 80-85 APIs have been developed for captive consumption; APIs developed in R&D will be manufactured in China under an asset-light model where factories have excess capacity for high volumes.
- Double-chamber PFS machine: In the process of installation for the Central America business.
- Manufacturing expansion: Two factories are up and running; the Onco injectable and API factories are to commence commercial production in April or May; OSD and Onco API will be completed in one or two years.
- Software development: Shop-floor software will serve as a tool for counter trade with factories in a few countries.
Geopolitics, Competition & Positioning
- Tariff risk assessed as low: Management believes medicine is the last or least affected by tariffs, noting that lifesaving drugs are not life-threatening to trade policy, though it acknowledged the need to monitor and ensure adequate derisking.
- China-to-U.S. exposure nil: The company does not sell from China to the U.S., so U.S. tariffs on China have no direct impact; management said it is "too early to say" what indirect effects might materialize.
- Acquisition strategy evolving: The company is considering acquiring a domestic company with domestic presence due to anti-globalization and protectionism trends, which could also help with brand marketing outside the country.
- No domestic India business: The company does no domestic business in India currently.
- Positioning as a unique player: Management wants to position the company as unique rather than competing head-to-head with larger players, believing the numbers will automatically follow.
C.C. Paarthipan: "Business being disrupted fast and it's time for us to be on the winning side, winning side of the disruption, I mean."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Caplin Steriles own-label launches | ~20 products launched (from 11 currently) | Before end of FY25 |
| Caplin Steriles own-label launches | ~50 products launched | Before end of next year |
| All 28 approved products launched | All 28 launched in U.S. | Within coming few weeks |
| FDA approvals for products under review | All 13 ANDAs under review approved | Within coming 12 months |
| U.S. revenue target | $100 million overall | FY27-FY28 |
| Onco injectable & API factories | Commence commercial production | April or May |
| OSD and Onco API facilities | Completed | One or two years from now |
| Chilean business | Start consistently | From July |
| Mexican business | Real growth to start | Maybe one year from now |
| Four high-tech products | Commercialization (outer limit) | 24 to 30 months |
| Latin America business | At least double | Next five years |
| Caplin Steriles own-label vs B2B mix | Own-label larger than B2B | Next 3-5 years |
| Margin improvement | Do better than before | After 3-3.5 years |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Total revenue growth | 16.7% YoY |
| LatAm business revenue growth (parent) | 14% YoY |
| U.S. business revenue growth | 23% YoY |
| Gross margin | 60.4%, second highest; last quarter was 60.9% |
| EBITDA margin | 36.9% |
| PBT margin | 33.8% |
| PAT margin | 26.7% |
| COGS as a percentage of revenue | 40%, down from 48% in FY19-20 |
| Operating expenses as a percentage of revenue | 25% to 26% |
| Caplin Steriles revenue | ₹87.8 crores |
| Caplin Steriles EBITDA | ₹24 crores |
| Oncology business turnover | ₹34 crores, turned positive in first full year of operations |
| Caplin Steriles USA (CSU) own-label revenue | $0.5 million, within first couple of months since November launch |
| ANDA approvals under Caplin's name | 28 approvals |
| Products under review with FDA | 13 products |
| Products launched under Caplin Steriles own label | 11 products so far |
| Effective tax rate (consolidated) | 20% |
| Free cash reserves | ₹1,081 crores |
| Liquid assets | ₹2,042 crores |